MLV Reiterates Buy On TG Therapeutics Following 3Q14 Update
MLV analyst Arlinda Lee reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $16 price target, as the company reported third- quarter earnings of ($0.51) vs. MLV’s last published estimate of ($0.22).
Lee noted, “TGTX reported 3Q14 earnings and quarter-end cash of $93M, which we estimate is sufficient through 2016 including 2 additional Phase 3 trials. Focus remains on clinical progress, and we look forward to TG-1101 and TGR-1202 data at ASH.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Arlinda Lee has a total average return of -2.7% and a 60.0% success rate. Lee is ranked #2619 out of 3367 analysts.